Neurology
FDA Approves High-Dose Nusinersen Regimen for Spinal Muscular Atrophy
The FDA has approved a high-dose nusinersen regimen for SMA, based on the DEVOTE study showing significant motor function improvements. The new dosing option launches in the US within weeks.
ChinaMedDirect Editorial